Joseph Edelman Net Worth

Joseph Edelman has an estimated net worth of $2.7 billion, according to Forbes Real-Time Billionaires, Joseph Edelman profile (figures as of October 20, 2026). That is up from $1.2 billion in 2019.

Joseph Edelman is an American hedge fund manager in finance and investments. He is best known as the founder, CEO, and portfolio manager of Perceptive Advisors, a New York-based firm that invests in healthcare and biotechnology. He started in biotech research on Wall Street, then moved through analyst and fund roles before launching his own firm in 1999. Over time, he became known for focusing on biotech stocks and for helping take life science companies public through SPAC deals.

His wealth comes from hedge fund investing. Edelman founded Perceptive Advisors in July 1999 with $6 million and built it into a much larger firm. The business had $4.1 billion by 2018, reached $8 billion in April 2023, and then $10 billion in July 2023. Forbes says he is self-made, and the magazine put his net worth at $2.7 billion on its real-time billionaires tracker as of October 20, 2026.

How Joseph Edelman built his fortune

Edelman made his name by specializing in biotech and healthcare investing. He began as a biotechnology analyst in 1987 at Wall Street Labe, Simpson & Company, then became a senior biotech analyst at Prudential Securities in 1990. In 1994, he joined Paramount Capital Asset Management and ran The Aries Funds until 1998. He then moved to First New York Securities in February 1999, where he managed an account backed with $6 million.

A few months later, he started Perceptive Advisors. The firm focused on finding promising technologies and innovations in biotechnology, and it grew far beyond its starting size. Perceptive also invested in small and mid-cap biotech companies such as CymaBay Therapeutics and Cerevel Therapeutics. Another part of Edelman’s career was helping set up ARYA Sciences Acquisition Corp I, II, III, IV, and V, which were created to support mergers, acquisitions, and public listings in biotech, pharmaceutical, and healthcare.

What moved his Forbes estimate

Forbes has tracked big swings in Edelman’s wealth as biotech markets and fund results changed. Its annual billionaires list placed him at $1.2 billion in 2019 and again in 2020, then higher in 2021 before moving lower in 2022, 2023, 2024, and 2025. Those changes matched a period when his main Perceptive Life Sciences hedge fund had an uneven run, including reported declines in 2021 and 2022 after a long stretch in which it lost money only twice in its first 20 years.

The picture improved later. According to the Forbes notes, his fund returned 83% in 2025, helped by biotech holdings such as Praxis Precision Medicines and Celcuity. That rebound came as Perceptive Advisors managed $10 billion and remained centered on biotechnology investing. Forbes valued Edelman at $2.7 billion in 2026, showing how closely his fortune is tied to biotech stock performance, hedge fund returns, and the scale of the firm he built.